Vol 14, No 1 (2018)
Guidelines / Expert consensus
Published online: 2018-02-28
Management of extravasation of antineoplastic agents
DOI: 10.5603/OCP.2018.0006
Oncol Clin Pract 2018;14(1):15-22.
Abstract
Not available
Keywords: chemotherpyextravasationcytotoxic drugscytostatic drugs
References
- Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49: 1796–1799.
- Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg. 2002; 49(4): 369–374.
- Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. ESMO Guidelines Working Group, ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7(5): vii167–vii173.
- Cosciato DA, Lowitz BB. Extravasation of antitumor agent. Man Clin Oncol. ; 1995: 479–480.
- Unseld M. Extravasation of chemotherapy. ESMO Handbook of Oncological Emergencies. ; 2016: 58–68.
- Dutcher JP, Wiernik P. Nagłe przypadki w hematologii i onkologii. PZWL 1993.
- Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol. 1987; 5(7): 1116–1126.
- Dorr RT, Alberts DS. Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep. 1983; 67(5): 499–501.
- Langer SW. Dextrazoxane in antracycline extravasation. J Clin Oncol. 2000; 18: 3064.
- Kretzschmar A. Extravasations of oxaliplatin. J. Clin. Oncol. 2003; 21(1): 4068.
- Bertelli G. Topical Dimethylsulfoxide for prevention of soft tissue injury after extravasation of vesicany cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995; 13: 2851–2855.
- Oliver IN. A prospective study of topical dimethylsulfoxide for treating anthracycline extravasation. J. Clin Oncol. 1988; 6: 1732–1735.
- Dorr RT. Antidotes to vesicant chemotherapy extravasation. Blood Rev. 1990; 4: 41–60.
- Schulmeister L. Managing vesicant extravasations. Oncologist. 2008; 13(3): 284–288.
- Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs. 2011; 27(1): 82–90.
- Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol. 2000; 27(3): 347–361.
- Schrijvers DL. Extravasation: a dreaded coplication of chemotherapy. Ann Oncol. 2003; 14(supl. 3): 26–30.
- Langer SW, Sehested M, Jensen P. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annals of Oncology. 2001; 12(3): 405–410.
- Kosmidis PA, Schrijvers D, Andre F, et al. Extravasation of chemotherapy. ESMO Handbook of oncological emergencies. Taylor & Francis. ; 2005: 37–43.
- Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004; 15: 858–662.
- Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016; 7(1): 87–97.